Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) had Return on Tangible Equity of 48.07% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$0.66M |
|
$4.80M |
|
$1.24M |
|
$-0.58M |
|
$9.30M |
|
$-8.64M |
|
$13.43M |
|
$4.80M |
|
$4.80M |
|
$4.80M |
|
$4.80M |
|
$4.80M |
|
$4.80M |
|
$-8.64M |
|
$-6.99M |
|
0.81M |
|
0.81M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$2.39M |
|
$9.19M |
|
$11.06M |
|
$13.45M |
|
$1.81M |
|
$0.26M |
|
$1.67M |
|
$3.47M |
|
$4.35M |
|
$9.98M |
|
$9.98M |
|
0.85M |
|
| Cash Flow Statement Financials | |
$-6.33M |
|
$-0.01M |
|
$3.44M |
|
$5.01M |
|
$2.10M |
|
$-2.92M |
|
$0.68M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.32 |
|
-- |
|
-- |
|
0.03 |
|
0.03 |
|
-88.15% |
|
-1312.77% |
|
-1312.77% |
|
-1062.16% |
|
728.88% |
|
728.88% |
|
$-6.35M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
2.22 |
|
164.19 |
|
110.25% |
|
|
Return on Tangible Equity |
48.07% |
35.66% |
|
46.85% |
|
$11.70 |
|
$-7.87 |
|
$-7.86 |
|